Drugs / MEDI5083
last change Jun 2020 re-read 2 minutes ago

MEDI5083

Developed for
cancer
Investigated by
MedImmune LLC

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03089645 Mar 2017 → Jun 2020 cancer MedImmune LLC Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MEDI5083 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03089645